Bavarian Nordic
174.2
DKK
+0.26 %
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+0.26%
-10.53%
-8%
-9.76%
-29.47%
+0.99%
+8.54%
-15.63%
+22.13%
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Read moreMarket cap
13.74B DKK
Turnover
80.91M DKK
Revenue
7.06B
EBIT %
21.28 %
P/E
9.07
Dividend yield-%
-
Financial calendar
5.3
2025
Annual report '24
9.4
2025
General meeting '25
9.5
2025
Interim report Q1'25
ShowingAll content types
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
Bavarian Nordic offentliggør foreløbige resultater for 2024 på linje med de opjusterede forventninger samt guider for 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025
Bavarian Nordic – Completion of Share Buy-Back Program
Bavarian Nordic – afslutning af aktietilbagekøbsprogram
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
Bavarian Nordic modtager positiv anbefaling fra de europæiske lægemiddelmyndigheder for chikungunyavaccine til personer i alderen 12 år og opefter
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic lancerer planlagt aktietilbagekøbsprogram for DKK 150 mio.
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
